This bill establishes the Hydrogen Infrastructure Finance and Innovation Act (HIFIA) pilot program to fund hydrogen infrastructure projects. It provides grants and low-cost loans (up to 80% of costs) to eligible entities like corporations, governments, and nonprofits building hydrogen pipelines, storage, or delivery systems - especially projects retrofitted for hydrogen blends or new pure-hydrogen lines. Priority is given to projects reducing emissions, minimizing environmental impact, serving disadvantaged communities, and creating U.S. jobs. The program requires mandatory leak monitoring and limits annual federal funding to $100 million for fiscal years 2024-2028.
SRES 90 designates March 2023 as "Endometriosis Awareness Month" and recognizes endometriosis as a chronic disease affecting millions of women in the U.S. The resolution specifically targets women with endometriosis - impacting roughly 1 in 10 women of reproductive age - and highlights the disease's debilitating symptoms, diagnostic delays, and healthcare burden. It requests federal health agencies (HHS, Defense, Veterans Affairs) to improve public education, update treatment resources, and advance research on endometriosis. As a non-binding resolution, it focuses on raising awareness and encouraging agency action, not enacting new laws or funding.
S 604, the "Changing the Culture of the FDA Act," requires the FDA to update its mission statement to explicitly include protecting public health by "strongly considering the danger of addiction and overdose death" when approving or regulating opioid medications. This bill directly affects the FDA's decision-making process for opioid-related drugs, mandating that addiction and overdose risks be a central factor in its reviews. The key provision is the formal amendment to the agency's mission statement, which would reshape how the FDA prioritizes public health considerations in opioid policy. The bill does not create new regulations but changes the foundational guidance for the agency's work on opioids.
S 606, the "Protecting Americans from Dangerous Opioids Act," requires the Health Secretary to revoke approval of an existing opioid drug whenever a new opioid is approved. Specifically, the Secretary must prioritize revoking non-abuse deterrent opioid formulations and consider public health impact when choosing which drug to remove. This directly affects opioid manufacturers and prescribers by reducing the number of less-safe opioid options available on the market. The bill targets the opioid crisis by linking new drug approvals to the removal of existing high-risk medications, based on data showing overdose deaths have quadrupled since 1999.
This bill directs the Secretaries of the Interior and Agriculture to identify at least 10 existing long-distance bike trails (minimum 80 miles on federal lands) and 10 potential development areas for such trails. It requires avoiding conflicts with existing uses like horseback riding, ensuring geographic representation, and creating maps/signage for identified trails. The bill mandates a report listing all identified trails within two years of enactment. It directly affects federal land managers (National Park Service, Forest Service) and bike trail users, focusing on planning and coordination rather than funding or construction.
This bill (S 607, the EFFECTIVE Act) requires the FDA to deny approval for new opioid painkiller drugs unless they demonstrate a significant safety or effectiveness advantage over existing comparable drugs. It directly affects pharmaceutical companies seeking to market new opioid analgesics by adding a new standard to the drug approval process. The key provision amends the Federal Food, Drug, and Cosmetic Act to give the FDA Secretary authority to reject opioid drug applications that don't meet this "significant advantage" threshold. This policy change aims to ensure new opioid medications offer meaningful benefits before reaching patients.
S 603 requires the FDA Commissioner to personally approve opioid drugs against an advisory committee's recommendation (instead of delegating the decision), directly affecting opioid drug approvals. It mandates detailed reports to Congress explaining the safety evidence supporting such approvals and disclosing any potential conflicts of interest involving FDA officials. The bill also prohibits marketing the drug until these reports are submitted to Congress. These provisions aim to increase transparency and accountability in FDA decisions on opioid medications.
This bill prohibits federally funded schools and athletic programs from allowing individuals assigned male at birth to participate in women's or girls' sports teams. It defines "sex" for this purpose solely based on biological sex assigned at birth, including reproductive anatomy and genetics. The law amends Title IX of the Education Amendments of 1972 to make such participation a violation of federal civil rights law. It directly affects all schools, colleges, and organizations receiving federal funds that operate athletic programs for women or girls.
This bill changes how often federal credit unions must hold board meetings based on their performance ratings. For all federal credit unions, boards must meet at least monthly for the first 5 years after their charter is approved. After that, credit unions rated 1 or 2 (highest performance) must meet at least 6 times yearly (with one per quarter), while those rated 3-5 must meet monthly. The bill directly affects all federal credit unions by adjusting their board meeting requirements according to their Uniform Financial Institutions Rating System score. These changes aim to align meeting frequency with credit union performance and oversight needs.
This bill directs the Federal Trade Commission (FTC) to study and report on practices in the pharmaceutical supply chain, focusing on pharmacy benefit managers (PBMs) and their impact on drug pricing. The FTC must submit an interim report within 180 days and a full report within one year, examining issues like whether PBMs steer patients to pharmacies they own, use proprietary data for competitive advantage, or design formularies to favor higher-cost drugs. The reports will also assess competition in the supply chain, legal barriers to enforcement, and the FTC’s ability to address anticompetitive behavior by drug manufacturers. The goal is to identify transparency gaps and recommend policy changes to improve competition and ensure consumers benefit from cost savings.
The Military Spouse Hiring Act expands the Work Opportunity Tax Credit to include military spouses. Employers who hire a spouse of an active-duty military member - certified by a local agency as meeting eligibility requirements on the hiring date - can claim this tax credit. The credit reduces the employer's federal tax liability for hiring such individuals. This provision applies to new hires after the bill's enactment date.
HR 1313, the Transparency in CFPB Cost-Benefit Analysis Act, requires the Consumer Financial Protection Bureau (CFPB) to include detailed cost-benefit analyses in all proposed financial regulations. The bill mandates that the CFPB explain the need for a regulation, assess costs and benefits for small businesses and the economy, evaluate alternatives, and justify decisions where benefits don't outweigh costs. It also requires consultation with the Small Business Administration if a rule increases costs for small businesses and a distribution analysis of burdens. This bill directly affects the CFPB's rulemaking process by increasing transparency in how financial regulations are developed.
